Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 5:18 AM
Ignite Modification Date: 2025-12-26 @ 4:26 AM
NCT ID: NCT04210427
Description: None
Frequency Threshold: 0
Time Frame: Overall time frame for the study: 2 years 4 months. Adverse events were recorded during and after the use of smartpill up to 2 weeks. For all three participants the period of collection of adverse event was 8 weeks. Informed consent and Baseline Rome questionnaire for GI symptoms - Week 1, Administer smart pill - Week 3,Collect transit time and related data - Week 4,Start Polyethylene Glycol - Week 5,Administer SmartPill again in 2 weeks - Week 7, Repeat the questionnaire - week 8
Study: NCT04210427
Study Brief: Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Intervention With Polyethylene Glycol & SmartPill Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy. Polyethylene Glycol 3350: All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks. SmartPill Motility System \& PillCam Patency Capsule: Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy. We did not collect the outcome details due to not adequate patients' participation. No adverse events were reported throughout the study. 0 None 0 3 0 3 View
Serious Events(If Any):
Other Events(If Any):